IP Library › Granted Patent US 7,375,180
Granted Patent B2
US 7,375,180 · App. 10/777,310 · Granted May 20, 2008

Methods and compositions related to IRM compounds and Toll-like receptor 8

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,180
App. No.
10/777,310
Granted
May 20, 2008
Kind
B2
Abstract

Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

Claims (17)

1. A pharmaceutical composition comprising a Toll-like receptor 8 (TLR8) agonist that comprises a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring, or a pharmaceutically acceptable salt thereof, in an amount effective to modulate at least one TLR8-mediated cellular signaling pathway in combination with a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a substituted imidazoquinoline amine.

3. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a tetrahydroimidazoquinoline amine.

4. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is an imidazopyridine amine.

5. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a 1,2-bridged imidazoquinoline amine.

6. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a 6,7-fused cycloalkylimidazopyridine amine.

7. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is an imidazonaphthyridine amine.

8. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a tetrahydroimidazonaphthyridine amine.

9. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is an oxazoloquinoline amine.

10. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a thiazoloquinoline amine.

11. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is an oxazolopyridine amine.

12. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a thiazolopyridine amine.

13. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is an oxazolonaphthyridine amine.

14. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a thiazolonaphthyridine amine.

15. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.

16. The pharmaceutical composition of claim 1 wherein the TLR8 agonist is a 1H-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine.

17. The pharmaceutical composition of claim 10 , wherein the thiazoloquinoline amine is 2-propylthiazolo[4,5-c]quinolin-4-amine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066433/0049 →